ArticleCureus2025
The Burden of Depression and Stigma Among Individuals With Tuberculosis Within the Integrated Tuberculosis-Mental Health Project: A Multisite Mixed-Methods Study Protocol.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Depressive symptoms and their associations with tuberculosis-related knowledge, attitudes, and practices among patients with multidrug-resistant tuberculosis.Frontiers in public health · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is a complex bidirectional relationship between tuberculosis (TB), major depressive disorder (MDD), and stigma. Despite the significant burden of these conditions in sub-Saharan Africa, only a few studies have explored their interplay. The primary aim of this study is to determine the burden of MDD and the dimensions of stigma among individuals with TB. The secondary aim is to assess the effectiveness of integrated TB-depression treatment compared to standard TB treatment. This will be a multistage study utilizing a mixed-methods design to address the research questions. Stage 1 will use a cross-sectional design to evaluate the burden of depression and stigma. Depression will be assessed using the Patient Health Questionnaire-9 (PHQ-9), and stigma will be measured using Van Rie's TB stigma scales - covering self-stigma, secondary stigma, community stigma, and stigma among healthcare workers. Stage 2 will involve a longitudinal follow-up of all eligible participants diagnosed with both TB and MDD. Participants will receive either integrated TB and MDD treatment or standard TB treatment, depending on their assigned site. Baseline assessments will include depressive symptomatology (PHQ-9) and perceived social support (Oslo Social Support Scale, OSSS). Follow-up assessments will occur at two weeks, eight weeks, and 24 weeks, using the same instruments. TB-related outcomes - including treatment continuation, interruption, default, and mortality - will also be recorded. Stage 3 will use a qualitative approach to explore the experience and dimensions of stigma from the perspectives of service users, their family members, and their communities. Weighted prevalence of MDD will be estimated with 95% CIs. The proportion of participants reporting experiences of stigma will be described using frequency counts and percentages. Changes in depressive symptoms over time between the two treatment groups will be analyzed using mixed ANOVA. Qualitative data will be analyzed thematically.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.